BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30566209)

  • 1. Reduction of left ventricular mass, left atrial size, and N-terminal pro-B-type natriuretic peptide level following alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Dąbrowski M; Kukuła K; Kłopotowski M; Bekta P; Śpiewak M; Mazurkiewicz Ł; Tyczyński P; Orczykowski M; Parma R; Witkowski A
    Kardiol Pol; 2019; 77(2):181-189. PubMed ID: 30566209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An assessment of regression of left ventricular hypertrophy following alcohol ablation of the interventricular septum in patients with hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.
    Dąbrowski M; Chojnowska L; Małek L; Spiewak M; Kuśmierczyk B; Koziarek J; Klisiewicz A; Miśko J; Witkowski A
    Kardiol Pol; 2012; 70(8):782-8. PubMed ID: 22933209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of 2D speckle tracking imaging in evaluating the effect of percutaneous intramyocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy.
    Qian D; Zhou X; Liu H; Cao L
    J Clin Ultrasound; 2021 Jul; 49(6):554-562. PubMed ID: 33675543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction.
    Kim SW; Park SW; Lim SH; Kwon SU; Choi YJ; Park MK; Lee SC; Lee SH; Park JE; Jeon ES
    Clin Cardiol; 2006 Apr; 29(4):155-60. PubMed ID: 16649724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic phase improvements in electrocardiographic and echocardiographic manifestations of left ventricular hypertrophy after alcohol septal ablation for drug-refractory hypertrophic obstructive cardiomyopathy.
    Matsuda J; Kitamura M; Takayama M; Imori Y; Shibuya J; Kubota Y; Sangen H; Nakamura S; Takano H; Asai K; Shimizu W
    Heart Vessels; 2018 Mar; 33(3):246-254. PubMed ID: 28965135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging.
    Park JR; Choi JO; Han HJ; Chang SA; Park SJ; Lee SC; Choe YH; Park SW; Oh JK
    Int J Cardiovasc Imaging; 2012 Apr; 28(4):763-72. PubMed ID: 21516440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
    Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
    Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Outcome After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: An Echocardiography and Cardiovascular Magnetic Resonance Imaging Study.
    Lu M; Du H; Gao Z; Song L; Cheng H; Zhang Y; Yin G; Chen X; Ling J; Jiang Y; Wang H; Li J; Huang J; He Z; Zhao S
    Circ Cardiovasc Interv; 2016 Mar; 9(3):e002675. PubMed ID: 26884612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Septal Reduction on Left Atrial Size and Diastole in Hypertrophic Cardiomyopathy.
    Finocchiaro G; Haddad F; Kobayashi Y; Lee D; Pavlovic A; Schnittger I; Sinagra G; Magavern E; Myers J; Froelicher V; Knowles JW; Ashley E
    Echocardiography; 2016 May; 33(5):686-94. PubMed ID: 26926154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy.
    Shelke AB; Menon R; Kapadiya A; Yalagudri S; Saggu D; Nair S; Narasimhan C
    Indian Heart J; 2016; 68(5):618-623. PubMed ID: 27773399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous alcohol septal ablation for hypertrophic obstructive cardiomyopathy: technical review and long-term clinical and echocardiographic outcomes.
    Leal S; Galeote G; Jiménez-Valero S; Sánchez-Recalde A; Salinas P; Ruiz AS; Orbe LC; Dominguéz F; Moreno R; López-Sendón JL
    Rev Port Cardiol; 2012 May; 31(5):363-71. PubMed ID: 22482474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short- and long-term outcome after alcohol septal ablation in obstructive hypertrophic cardiomyopathy: Experience of a reference center.
    Aguiar Rosa S; Fiarresga A; Galrinho A; Cacela D; Ramos R; de Sousa L; Gonçalves A; Bernardes L; Patrício L; Branco LM; Ferreira RC
    Rev Port Cardiol (Engl Ed); 2019 Jul; 38(7):473-480. PubMed ID: 31495717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An assessment of left atrial function in patients with hypertrophic obstructive cardiomyopathy before and 1 year after septal ablation by two-dimensional speckle tracking echocardiography.
    Fang H; Tang H; Li P; Xiong L; Hu G; Li L; Yu Y; Zhao B
    Echocardiography; 2017 Mar; 34(3):407-414. PubMed ID: 28130861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.
    Alam M; Dokainish H; Lakkis N
    J Interv Cardiol; 2006 Aug; 19(4):319-27. PubMed ID: 16881978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to significant gradient reduction following septal balloon occlusion predicts the magnitude of final gradient response during alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Almasood A; Garceau P; Woo A; Rakowski H; Schwartz L; Overgaard CB
    JACC Cardiovasc Interv; 2011 Sep; 4(9):1030-4. PubMed ID: 21939945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis.
    Veselka J; Faber L; Liebregts M; Cooper R; Januska J; Kashtanov M; Dabrowski M; Hansen PR; Seggewiss H; Hansvenclova E; Bundgaard H; Ten Berg J; Stables RH; Jensen MK
    Eur Heart J; 2019 Jun; 40(21):1681-1687. PubMed ID: 31152553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of immediate decrease in ventricular septal strain after alcohol septal ablation for obstructive hypertrophic cardiomyopathy to long-term reduction in left ventricular outflow tract pressure gradient.
    van Ramshorst J; Mollema SA; Delgado V; van der Wall EE; Schalij MJ; Atsma DE; Bax JJ
    Am J Cardiol; 2009 Jun; 103(11):1592-7. PubMed ID: 19463521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy.
    Arteaga E; Araujo AQ; Buck P; Ianni BM; Rabello R; Mady C
    Am Heart J; 2005 Dec; 150(6):1228-32. PubMed ID: 16338263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy.
    van Dockum WG; Beek AM; ten Cate FJ; ten Berg JM; Bondarenko O; Götte MJ; Twisk JW; Hofman MB; Visser CA; van Rossum AC
    Circulation; 2005 May; 111(19):2503-8. PubMed ID: 15867172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.